Cassava Announces Closure of U.S. Department of Justice Investigation
AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the U.S. Department of Justice Fraud Section (DOJ) has closed its inquiry into the Company regarding allegations of research misconduct as described in the indictment in United States v. Wang, 8:24-cr-000211-TDC (D. Md.). That indictment was dismissed with prejudice by DOJ on October 23, 2025.
As previously disclosed, the Company reached a settlement with the U.S. Securities and Exchange Commission (SEC) of negligence-based disclosure charges in September 2024 and paid a monetary penalty without admitting or denying the SEC’s allegations.
The Company cooperated fully with both the DOJ and SEC investigations. These outcomes end the investigations of the Company by the DOJ and SEC.
“We welcome the resolution of these investigations and remain dedicated to maintaining the trust of all our stakeholders. As we move forward, we will continue to focus our efforts on developing a novel treatment for TSC-related epilepsy,” said Richard J. Barry, President and Chief Executive Officer of Cassava.
About Cassava Sciences, Inc.
Cassava Sciences, Inc. (NASDAQ: SAVA), is a biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and potentially other indications.
For more information, please visit: https://www.CassavaSciences.com
Company
Eric Schoen, Chief Financial Officer
(512) 501-2450
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Signet Jewelers Raises Full-Year Earnings Outlook as Fiscal Second-Quarter Profit Tops Estimates
Battery weight reduced by 40% and freed from germanium constraints! Rocket Lab (RKLB.US) lightweight battery taps into the incremental market for space AI
"While IMM Apex delivers exceptional performance, it has also addressed real-world challenges such as rising material costs and supply chain constraints," said Rocket Lab USA President Brad Clevenger.
US Stock Market Preview: All Three Major Index Futures Fall, Brent Oil Surges Past $100, Besant to Announce US Treasury Repo Scale, Apple Event Incoming
On Wednesday, September 9th, before the U.S. stock market opened, futures for the three major U.S. stock indexes all declined.
The ultimate bottleneck for AI is not just electricity, but also the electricity bill! As data centers become a focus in the US elections, AI infrastructure investment faces a "ballot stress test"
In 2026, data center spending, as the backbone of the artificial intelligence industry, will reach a record high. However, alongside the boom in infrastructure construction, opposition to data centers has risen sharply this year. What started as a localized issue has quickly evolved into a key topic for the November midterm elections.
Crypto prices
More
